Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 13,620 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Melanoma
Interventions: Skin Self- examination structured training; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Skin Ulcers, Sickle Cell Anemia
Interventions: Arginine Butyrate, Standard local care dressing; Drug · Other
Lead sponsor: Susan P. Perrine; Other
Eligibility: 16 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more

Conditions: Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IV Melanoma
Interventions: saracatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psoriasis
Interventions: CEP-701 20mg, CEP-701 40mg, CEP-701 60mg, CEP-701 80mg; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Dallas, Texas • Norfolk, Virginia

Conditions: Psoriasis, Skin Diseases
Interventions: Orismilast modified release tablets, Placebo; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Cromwell, Connecticut • Washington D.C., District of Columbia • Beverly, Massachusetts + 3 more

Conditions: Alopecia Areata(AA)
Interventions: HCW9302, an IL-2 fusion protein; Drug
Lead sponsor: HCW Biologics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio

Conditions: Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions: Allogeneic natural killer (NK) cell; Genetic
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more

Conditions: Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers, Breast Cancer, Gastric (Stomach) Cancer, Colorectal (Colon or Rectal) Cancer, Sarcoma, Ovarian Adenocarcinoma, Uterine Adenocarcinoma, Endometrial Adenocarcinoma, Esophageal Adenocarcinoma, Head and Neck Cancer, Therapy-Related Acute Myeloid Leukemia, Therapy-Related MDS, Clonal Hematopoiesis of Indeterminate Potential (CHIP), Clonal Cytopenia of Undetermined Significance
Interventions: Samples; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Best Practice, Internet-Based Intervention, Survey Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 15 Years to 39 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio

Conditions: Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions: p53: 264-272 peptide, CT-011; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Carcinoma
Interventions: Cryotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Urbana, Illinois • Grand Rapids, Michigan • Rochester, Minnesota + 5 more

Conditions: Generalized Pustular Psoriasis
Interventions: Imsidolimab; Biological
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Encino, California • Largo, Florida • Miami, Florida + 2 more

Conditions: ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Interventions: Giredestrant; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 9
States / cities: Anchorage, Alaska • Fountain Valley, California • Redlands, California + 6 more

Conditions: Metastatic HER2+ Advanced Breast Cancer
Interventions: Tucatinib, Trastuzumab, Capecitabine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms
Interventions: Individually tailored education and guided application to promote activity participation, Individually tailored guided application, Individually tailored education, Priority elicitation, Static education and guided application, Static guided application, Static education, Information; Behavioral
Lead sponsor: MGH Institute of Health Professions; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasms
Interventions: MST-997; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Nashville, Tennessee

Conditions: Menkes Disease
Interventions: copper histidinate; Drug
Lead sponsor: Sentynl Therapeutics, Inc.; Industry
Eligibility: 0 Years to 6 Years
U.S. locations: 20
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 17 more

Conditions: Complicated Skin and Skin Structure Infections
Interventions: JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 27
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 23 more

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 26 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma
Interventions: ALVAC-MART-1 vaccine, MART-1:26-35(27L) peptide vaccine, Aldesleukin, autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, incomplete Freund's adjuvant; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Actinic Keratosis
Interventions: Photodynamic therapy (PDT), Vitamin D3; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel; Radiation · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasm Female, Early Detection of Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Magnetic Resonance Imaging
Interventions: Enhanced Usual Care, Decision Support; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions: mHSCT, cyclophosphamide; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more

Search by objective public record fields.

Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Optimizing Functional Recovery After Breast Cancer Treatment

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Copper Histidinate Treatment for Menkes Disease

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

Registry for Systemic Eczema Treatments

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

Scleroderma: Cyclophosphamide or Transplantation